Pacific Biosciences Of California (PACB) Cash & Equivalents (2010 - 2026)

Pacific Biosciences Of California's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $56.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 3.82% year-over-year to $56.3 million in Q1 2026; TTM through Mar 2026 was $56.3 million, a 3.82% decrease from a year earlier, with the FY2025 full-year figure at $63.7 million, up 2767.1% from the prior year.
• Cash & Equivalents slipped to $56.3 million in Q1 2026 per PACB's latest filing, from $63.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $353.8 million in Q1 2023 and bottomed at $1.8 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $5.5 million (2022), against an average of $76.7 million.
• Across the five-year window, Cash & Equivalents surged 9307.42% in 2022 and slumped 99.12% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $3.2 million in 2022, then slipped by 15.52% to $2.7 million in 2023, then declined by 18.37% to $2.2 million in 2024, then jumped by 2767.1% to $63.7 million in 2025, then retreated by 11.67% to $56.3 million in 2026.
• Per Business Quant, the three latest PACB Cash & Equivalents figures stand at $56.3 million (Q1 2026), $63.7 million (Q4 2025), and $1.8 million (Q3 2025).